Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

216 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O; ESC Scientific Document Group. Mach F, et al. Among authors: pedersen tr. Eur Heart J. 2020 Jan 1;41(1):111-188. doi: 10.1093/eurheartj/ehz455. Eur Heart J. 2020. PMID: 31504418 Free article. No abstract available.
Erratum to "2019 ESC/EAS guidelines for the management of dyslipidemias: Lipid modification to reduce cardiovascular risk" [Atherosclerosis 290 (2019) 140-205].
Authors/Task Force Members; ESC National Cardiac Societies; ESC Committee for Practice Guidelines (CPG). Authors/Task Force Members, et al. Atherosclerosis. 2020 Jan;292:160-162. doi: 10.1016/j.atherosclerosis.2019.11.020. Epub 2019 Dec 4. Atherosclerosis. 2020. PMID: 31811963 No abstract available.
Evolocumab in Patients with Cardiovascular Disease.
Sabatine MS, Giugliano RP, Pedersen TR. Sabatine MS, et al. Among authors: pedersen tr. N Engl J Med. 2017 Aug 24;377(8):787-8. doi: 10.1056/NEJMc1708587. N Engl J Med. 2017. PMID: 28834471 Free article. No abstract available.
Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: A Prespecified Secondary Analysis From the FOURIER Trial.
Gencer B, Mach F, Murphy SA, De Ferrari GM, Huber K, Lewis BS, Ferreira J, Kurtz CE, Wang H, Honarpour N, Keech AC, Sever PS, Pedersen TR, Sabatine MS, Giugliano RP. Gencer B, et al. Among authors: pedersen tr. JAMA Cardiol. 2020 Aug 1;5(8):952-957. doi: 10.1001/jamacardio.2020.0882. JAMA Cardiol. 2020. PMID: 32432684 Free PMC article.
Congestive heart failure is associated with lipoprotein components in statin-treated patients with coronary heart disease Insights from the Incremental Decrease in End points Through Aggressive Lipid Lowering Trial (IDEAL).
Holme I, Strandberg TE, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Larsen ML, Lindahl C, Pedersen TR; Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group. Holme I, et al. Among authors: pedersen tr. Atherosclerosis. 2009 Aug;205(2):522-7. doi: 10.1016/j.atherosclerosis.2009.01.023. Epub 2009 Jan 24. Atherosclerosis. 2009. PMID: 19327776 Clinical Trial.
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).
Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, Kuder J, Murphy SA, Jukema JW, Lewis BS, Tokgozoglu L, Somaratne R, Sever PS, Pedersen TR, Sabatine MS. Bonaca MP, et al. Among authors: pedersen tr. Circulation. 2018 Jan 23;137(4):338-350. doi: 10.1161/CIRCULATIONAHA.117.032235. Epub 2017 Nov 13. Circulation. 2018. PMID: 29133605 Free article. Clinical Trial.
LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial.
Vallejo-Vaz AJ, Packard CJ, Ference BA, Santos RD, Kastelein JJP, Stein EA, Catapano AL, Pedersen TR, Watts GF, Ray KK. Vallejo-Vaz AJ, et al. Among authors: pedersen tr. Atherosclerosis. 2021 Mar;320:1-9. doi: 10.1016/j.atherosclerosis.2021.01.003. Epub 2021 Jan 12. Atherosclerosis. 2021. PMID: 33497862
Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.
Gitt AK, Drexel H, Feely J, Ferrières J, Gonzalez-Juanatey JR, Thomsen KK, Leiter LA, Lundman P, da Silva PM, Pedersen T, Wood D, Jünger C, Dellea PS, Sazonov V, Chazelle F, Kastelein JJ; DYSIS Investigators. Gitt AK, et al. Eur J Prev Cardiol. 2012 Apr;19(2):221-30. doi: 10.1177/1741826711400545. Epub 2011 Mar 10. Eur J Prev Cardiol. 2012. PMID: 21450578
High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies.
van der Steeg WA, Holme I, Boekholdt SM, Larsen ML, Lindahl C, Stroes ES, Tikkanen MJ, Wareham NJ, Faergeman O, Olsson AG, Pedersen TR, Khaw KT, Kastelein JJ. van der Steeg WA, et al. Among authors: pedersen tr. J Am Coll Cardiol. 2008 Feb 12;51(6):634-42. doi: 10.1016/j.jacc.2007.09.060. J Am Coll Cardiol. 2008. PMID: 18261682 Free article. Clinical Trial.
216 results